Tomasz M. Beer - Concepedia

Author

Tomasz M. Beer

Oregon Health & Science University ORCID

Also Known As

New Brunswick, Small, Eric J., T Beer, T M Beer, T. BEER, T. Beer, T. M. Beer, T.M Beer, T.M. Beer, TOMASZ M. BEER

791

Publications

37.2K

Citations

H-Index

173

Concepts

All Affiliations

Oregon Health & Science University Portland VA Medical Center University of Washington University of California, San Francisco Memorial Sloan Kettering Cancer Center

About

Tomasz M. Beer is an author at Oregon Health & Science University specializing in medicine, oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	49	125	15.4K
2	Health Sciences	19	29	3K
3	Natural Sciences	2	2	226
4	Nursing	2	2	32
5	Engineering	1	1	291

Tomasz M. Beer

256

Publications

35.1K

Citations

H-Index

Page 1

	Year	Citations
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf, New England Journal of Medicine	2014	3K
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer Oliver Sartor, Johann S. de Bono, Kim N., New England Journal of Medicine	2021	2.3K
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer Chris Tran, Samedy Ouk, Nicola J. Clegg, Science Androgen ReceptorMedicinal ChemistryUrologySecond-generation AntiandrogenGenitourinary Cancer	2009	2.3K
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group Howard I. Scher, Susan Halabi, Ian F. Tannock, Journal of Clinical Oncology	2008	2.2K
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 Howard I. Scher, Michael J. Morris, Walter M. Stadler, Journal of Clinical Oncology	2016	1.5K
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial Eugene D. Kwon, Charles G. Drake, H. I. Scher, The Lancet Oncology UrologyOncologyDocetaxel ChemotherapyClinical TrialsImmune Checkpoint Inhibitor	2014	1.5K
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study Howard I. Scher, Tomasz M. Beer, Celestia S. Higano, The Lancet UrologyOncologyMedicineCastration-resistant Prostate CancerAnti-cancer Agent	2010	1.1K
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study Rahul Aggarwal, Jiaoti Huang, Joshi J. Alumkal, Journal of Clinical Oncology T-scnc DetectionUrologyGenitourinary CancerMedicinePathology	2018	776
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B Yu Sun, Judith Campisi, Celestia S. Higano, Nature Medicine UrologyOncologyTreatment-induced DamageMedicineTumor Suppressor	2012	774
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer Tomasz M. Beer, Eugene D. Kwon, Charles G. Drake, Journal of Clinical Oncology PharmacotherapyImmunotherapeuticsImmunotherapyMinimally Symptomatic PatientsPhase Iii Trial	2016	742

Page 1